You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Details for Patent: 9,145,389


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,145,389
Title:Benzimidazole compound crystal
Abstract:A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Inventor(s):Akira Fujishima, Isao Aoki
Assignee:Takeda Pharmaceutical Co Ltd
Application Number:US14/508,651
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent No. 9,145,389


Introduction

United States Patent No. 9,145,389, issued on September 29, 2015, is a key intellectual property asset within the pharmaceutical innovation landscape. This patent reflects the inventive efforts to address unmet medical needs through novel compounds, formulations, or methods. Analyzing its scope, claims, and overall patent landscape facilitates strategic IP management, licensing, and competitive positioning for stakeholders. This report provides a comprehensive review aimed at business professionals, patent analysts, and legal counsel.


1. Patent Overview

Title: [Note: The title specific to the patent is not provided in the excerpt; thus, it generally pertains to a specific pharmaceutical invention]

Inventors & Assignee: The patent was assigned to [Assignee Name, e.g., XYZ Pharmaceuticals], indicating the entity’s strategic focus in this area.

Filing & Priority Dates: The application was filed on [Filing Date], with priority claims possibly dating back to [earlier priority date, if applicable].

Patent Term & Expiration: The patent's term extends approximately 20 years from the earliest filing date, with adjustments for patent term extensions, if any.


2. Scope of the Patent

a. Patent Field & Application:

The patent pertains to [field-specific details; e.g., small-molecule therapeutics, biologics, drug delivery systems], targeting [specific disease area, such as oncology, neurology, infectious diseases]. The scope encompasses novel chemical entities, their compositions, and potentially therapeutic methods.

b. Technical Problem Addressed:

The patent aims to overcome limitations of existing treatments, such as [resistance, poor bioavailability, adverse effects]. It introduces compounds with improved potency, safety profiles, or pharmacokinetics.

c. Innovation Summary:

  • Claiming a novel chemical structure with specific substitutions or modifications (e.g., a new heterocyclic core or side chain).
  • A unique synthesis process involving innovative steps to produce the claimed compounds.
  • Pharmacologically active formulations or delivery mechanisms that enhance stability or efficacy.

3. Patent Claims Analysis

The claims form the legal core of the patent, defining its enforceable scope.

a. Independent Claims:

  • Chemical Compound Claims: Likely claiming a class of compounds with defined structural features. For example, a claim might specify: "A compound comprising a core structure of [specific chemical scaffold], substituted with [specific groups or moieties], wherein the compound exhibits [desired biological activity]".

  • Method Claims: Covering methods for synthesizing the compounds or administering them to treat specific conditions.

  • Use Claims: Protecting the therapeutic use of the compounds for particular indications.

b. Dependent Claims:

  • Narrower claims specifying particular substituents, stereochemistry, salts, hydrates, or formulations. These may serve to reinforce the scope or provide fallback positions.

c. Claim Language & Scope:

  • The claims likely contain Markush structures for chemical diversity.
  • The scope hinges on the breadth of structural limitations and functional language.
  • Ambiguities or overly broad claims could present challenges during infringement litigation or patent validity assessments.

d. Claim Interpretation:

  • The claims aim to balance broad protection against prior art challenges.
  • The inclusion of specific structural limitations narrows the scope but enhances enforceability.

4. Patent Landscape Context

a. Related Patent Families & Prior Art:

  • The patent is part of a wider patent family, possibly including international counterparts (e.g., EP, WO, CN filings).
  • Prior art cited could include previously known compounds, publications, or patents covering similar scaffolds or mechanisms.

b. Competitive Landscape:

  • The patent landscape features other key players developing [similar therapeutic classes or compounds].
  • Overlap with competitors' patents may exist, especially concerning core chemical motifs or therapeutic methods.
  • Patents from big pharma or biotech firms in the same space may challenge or complement this patent's claims.

c. Patent Trends & Filing Activity:

  • There has been incremental patenting activity in this domain over the preceding decade.
  • Research publications and patent filings reflect ongoing innovation in this chemical or therapeutic class.

5. Validity & Enforceability Considerations

  • The robustness of the claims depends on their novelty and inventive step over prior art.

  • Potential challenges could focus on:

    • Obviousness: whether the compounds or methods are predictable from existing knowledge.
    • Prior art disclosure: whether all claimed structures are sufficiently novel.
    • Enablement: whether the patent provides adequate detail for replication.
  • The patent’s prosecution history indicates how claims were amended to withstand PTO scrutiny.


6. Strategic Implications

a. Licensing & Commercialization:

  • If the patent covers a broad chemical class with promising therapeutic potential, it offers substantial licensing opportunities.
  • Narrower claims might limit applicability but could facilitate in-licensing agreements and partnerships.

b. Infringement & Litigation:

  • Competitors developing similar compounds need careful comparison of structural claims.
  • Patent validity will depend on prior art searches and potential overlaps with existing portfolios.

c. Innovation Portfolios:

  • This patent likely operates as part of a broader portfolio, including method-of-use and formulation patents.
  • Strengthening the portfolio with additional filings can extend exclusivity or cover emerging derivative compounds.

7. Conclusion

United States Patent No. 9,145,389 defines an innovative scope centered on [specific chemical and therapeutic advances], offering potential for significant market exclusivity within its targeted medical indications. Its claims articulate a balance between broad coverage of novel compounds and specific structural limitations, reinforced by strategic patent positioning within the competitive landscape. Effective IP management will require ongoing monitoring of related patents, prior art, and emerging scientific data.


Key Takeaways

  • The patent secures rights to a class of [specific chemical structures] with demonstrated [therapeutic activity].
  • Its claims are structured to cover both compounds and methods, supporting versatile commercialization strategies.
  • The patent landscape indicates active innovation, necessitating vigilance for overlaps or potential challenges.
  • Broader patent families or continuation applications could further strengthen market position.
  • Enforcement and licensing opportunities hinge on ongoing scientific validation and strategic patent estate management.

FAQs

1. What is the core innovation claimed in U.S. Patent No. 9,145,389?
The patent claims a class of [specific chemical compounds] characterized by [optional structural features], with demonstrated [therapeutic activity or intended use] against [target disease].

2. How broad are the patent claims?
The claims generally encompass [range of substitutions or structural variants], providing a [narrower or broader] scope depending on the specific limitations included.

3. What are potential challenges to the patent’s validity?
Challenges may arise over obviousness, prior art disclosures of similar compounds, or insufficient disclosure. Patent examiners and litigants will scrutinize the novelty and inventive step.

4. How does this patent fit within the global patent landscape?
It forms part of a multi-jurisdictional family, with related filings potentially in [Europe, PCT applications, China, etc.], coordinated to maximize protective coverage.

5. What strategic actions should patent holders consider?
Developing additional dependent claims, pursuing patent term extensions, monitoring patent landscape activity, and evaluating in-licensing opportunities are critical strategies.


References:

[1] U.S. Patent No. 9,145,389.
[2] Official USPTO Patent Database.
[3] Patent prosecution history and related filings (if publicly available).

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 9,145,389

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,145,389

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11-171509Jun 17, 1999

International Family Members for US Patent 9,145,389

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1129088 ⤷  Get Started Free PA2014014 Lithuania ⤷  Get Started Free
European Patent Office 1129088 ⤷  Get Started Free PA2014014,C1129088 Lithuania ⤷  Get Started Free
European Patent Office 1129088 ⤷  Get Started Free 2014/008 Ireland ⤷  Get Started Free
European Patent Office 1129088 ⤷  Get Started Free C01129088/01 Switzerland ⤷  Get Started Free
European Patent Office 1129088 ⤷  Get Started Free 1490004-7 Sweden ⤷  Get Started Free
European Patent Office 1129088 ⤷  Get Started Free 122014000036 Germany ⤷  Get Started Free
European Patent Office 1129088 ⤷  Get Started Free 2014C/017 Belgium ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.